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Poly-N-acetyl-glucosamine (PNAG) is a staphylococcal surface polysaccharide influencing biofilm formation
that is also under investigation for its vaccine potential. Antibodies that bind to PNAG with either low (<15%)
or high (>90%) levels of acetate are superior at opsonic and protective activity compared with antibodies that
bind to PNAG with only high levels (>70%) of acetate. PNAG is synthesized by four proteins encoded within
the intercellular adhesin (ica) locus icaADBC. In Staphylococcus epidermidis, icaB encodes a deacetylase needed
for the surface retention of PNAG and optimal biofilm formation. In this study, we confirmed that icaB plays
a similar role in Staphylococcus aureus and found that an icaB mutant of S. aureus expressed significantly less
surface-associated PNAG, was highly susceptible to antibody-independent opsonic killing that could not be
enhanced with antibody raised against deacetylated PNAG (dPNAG), and had reduced survival capacity in a
murine model of bacteremia. In contrast, an icaB-overexpressing strain produced primarily surface-associated
PNAG, was more susceptible to opsonophagocytosis with antibody to dPNAG, and had increased survival in a
murine bacteremia model. The highly acetylated secreted PNAG was more effective at blocking opsonic killing
mediated by a human monoclonal antibody (mAb) to native PNAG than it was at blocking killing mediated by
a human mAb to dPNAG, which by itself was a more effective opsonin. Retention of dPNAG on the surface of
S. aureus is key to increased survival during bacteremia and also provides a molecular mechanism explaining
the superior opsonic and protective activity of antibody to dPNAG.
Staphylococcus aureus and coagulase-negative staphylococci
are the most frequent causes of nosocomial bloodstream in-
fections (43). A critical virulence determinant in such infec-
tions is the production of a high-molecular-weight polymer of
-1-6-linked N-acetyl-glucosamine (PNAG) that is involved in
adherence to polymeric substrates, bacterial intercellular ad-
hesion, biofilm formation, and protection against antibody-
independent opsonic killing (3, 4, 15, 26, 40). Proteins encoded
by the icaADBC genes of the intercellular adhesin (ica) locus
synthesize PNAG (6, 10–12, 30, 31). IcaA is a trans-membrane
glucosyltransferase and can synthesize short PNAG polymers
in vitro using UDP-N-acetyl-glucosamine as a substrate (10).
IcaD increases the biosynthetic efficiency of IcaA (10). IcaC is
also a transmembrane protein and appears to be involved in
linking short polymers to make longer oligomers of PNAG
(10). In its mature form, PNAG, also referred to by some
researchers as polysaccharide intercellular adhesin (PIA) (12,
44), is a mixture of polymers such that about 10 to 20% of the
amino groups are not acetylated, which could give some of the
polymers within the polysaccharide complex a net positive
charge (16, 27). It is not known whether PNAG consists of a
minority of highly deacetylated molecules mixed in with a
majority of highly acetylated molecules or if there is a range of
acetyl substituents spread over individual molecules.
In a recent study of PNAG (called PIA) synthesis in Staph-
ylococcus epidermidis, it was shown that IcaB exhibits deacety-
lase activity (40). In that same study, those authors demon-
strated that the IcaB-induced partial deacetylation of PNAG is
necessary for its association with the bacterial cell surface and
that this association is required for biofilm formation and for
PNAG-mediated evasion of phagocytosis. In S. epidermidis, a
loss of the icaB gene resulted in the reduced persistence of one
strain in a murine model of device-related infection (40). How-
ever, while several studies have shown that PNAG produced by
S. epidermidis is an important virulence factor for coagulase-
negative staphylococcus infections involving biofilm formation
on implanted biomaterials (25, 37, 38), this has not been found
to be the case with S. aureus biomaterial implant infections (8,
9, 21). Other studies indicated that for S. aureus, PNAG may
be more important as a virulence factor for infections involving
the systemic spread of the organism, as a recent study showed
that the loss of the ica locus in S. aureus significantly decreased
the virulence of three S. aureus strains in three murine models:
bacteremia, renal infection, and lethal sepsis following perito-
nitis (22). However, in one S. aureus strain, strain Newman,
PNAG did not appear to be a virulence factor in a murine
model of pneumonia (42). Thus, it appears that there may be
somewhat different roles for PNAG in the virulence of S.
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epidermidis versus S. aureus as well as differences in PNAG-
dependent virulence in different anatomic sites of infection.
Whether virulence is affected by the loss of IcaB deacetylase
activity in S. aureus infections where PNAG elaboration is
important has not been determined.
In addition, PNAG has been used as a target antigen in a
strategy to develop an antistaphylococcal vaccine (16, 27–29).
We recently reported that antibodies raised against diphtheria
toxoid-conjugated, highly acetylated (90%) PNAG lacked
protective efficacy against PNAG-positive S. aureus strains and
exhibited significantly lower opsonic killing than antibodies
raised against diphtheria toxoid-conjugated chemically deacet-
ylated PNAG (dPNAG) (15% acetylation) (29). In addition,
in contrast to antibodies to highly acetylated PNAG, the anti-
bodies to dPNAG were protective in murine models of bacte-
remia and lethal peritonitis (29). Confirmatory findings were
reported for human antibodies to native PNAG and dPNAG
based on the properties of affinity-purified antibodies obtained
from the sera of S. aureus-infected cystic fibrosis patients (20).
Given that Vuong et al. (40) previously demonstrated that
IcaB in S. epidermidis is a PNAG deacetylase, and that anti-
bodies raised against highly acetylated PNAG are not opti-
mally protective in mice, we hypothesized that the superior
opsonic and protective activity of antibodies to the deacety-
lated form of dPNAG was related to the preferential surface
retention of this form of the antigen. Such retention would
obviously be essential for effective opsonic killing and protec-
tion mediated by antibody specific to this isoform of PNAG. In
addition, we evaluated whether secreted, highly acetylated,
native PNAG, which can bind antibody raised against dPNAG
(29), can act as a decoy antigen, allowing S. aureus to evade
antibody to PNAG. To test these hypotheses, we constructed
in-frame icaB deletion mutants and icaB-overexpressing
strains in S. aureus strain 10833, evaluated the surface reten-
tion and secretion of PNAG, and correlated these findings with
biologic outcomes using biofilm formation in vitro, opsonic
killing assays, and in vivo outcomes in a murine model of S.
aureus bacteremia.
MATERIALS AND METHODS
Staphylococcal strains and media. S. aureus strain MN8, obtained from a
patient with toxic shock syndrome, was provided by Patrick Schlievert (Minne-
apolis, MN). Strain MN8m is a spontaneous mutant isolated from a chemostat
culture of strain MN8 that overproduces PNAG due to a 5-bp deletion in the
middle of the promoter for the ica locus (13). S. aureus strain NCTC 10833
(ATCC 25904) is a clumping factor-positive variant of a throat swab isolate.
Partial deletion of the ica locus to produce S. aureus strain 10833ica::tet was
performed as described previously by Cramton et al. (6). The strains were grown
at 37°C on tryptic soy agar plates containing the appropriate antibiotic. Liquid
cultures were grown in either tryptic soy broth (TSB) lacking glucose (17 g/liter
peptone from casein, 3 g/liter peptone from soymeal, 5 g/liter NaCl, 2.5 g/liter
K2HPO4) or TSB plus an additional 1% glucose (TSBG).
Plasmids, primers, and cloning and expression of genes in the ica locus. All
plasmid purifications were performed with the QIAprep Spin Miniprep kit
(QIAGEN, Valencia, CA). All primers were custom synthesized by QIAGEN
Operon (Alameda, CA). Restriction enzymes and DNA-modifying enzymes were
purchased from Invitrogen. Plasmid pMUC was derived using a previously de-
scribed vector (13) by ligating the constitutively transcribed ica locus from strain
MN8m into the shuttle vector pRB473. To create plasmid pMUCicaB, a non-
polar, in-frame deletion which removed more than 80% of the icaB gene was
generated by amplifying the plasmid by PCR with the following primer pair:
icaBdelFWD (5-CCATCCAGTGTGCTTACAGGC-3) and icaBdelREV (5-
TCCATTAAGAGATGGGACGGATTCC-3). The ends of the PCR product
were phosphorylated using T4 kinase, and the linear DNA was circularized using
Ready-2-Go T4 ligase (Amersham). The plasmid was sequenced at the Harvard
Medical School Microbiology Core Facility to confirm that the icaB deletion did
not cause a frameshift mutation and that the rest of the ica locus was free from
any other mutations. The plasmid was transduced into S. aureus 10833ica::tet to
trans-complement the chromosomally deleted ica locus and produce S. aureus
strain 10833ica::tetpMUCicaB.
In order to construct a vector for the constitutive transcription of inserted
DNA, the ica promoter was amplified from genomic DNA in the ica-constitutive
strain MN8m by PCR using the primer pair icaprovectorFWD (5-GGGGGAT
CCCCCTACTGAAAATTAATCACACTATG-3) and icaprovectorREV (5-C
CCCCCGGGCAATTTCTTTACCTACCTTTCGTTAG-3) and cloned into the
SmaI and BamHI sites of pRB473 to produce plasmid pKJ3. The icaB gene was
amplified from MN8 genomic DNA using primers icaBFWD (5-GTGAAGTA
TAGAAAATTTATAATTTTAGTGTTGAG-3) and icaBREV (5-GGGGAG
CTCCTAATCTTTTTCATGGAATCCGTCC-3), digested with SstI, and
cloned into pKJ3 to create picaB. All plasmid constructs were initially trans-
formed into the restriction-deficient S. aureus strain RN4220 according to a
method described previously by Lee (23). Constructs were transferred to other
strains of S. aureus by transduction using phage 80 (18).
RT-PCR. S. aureus cultures were grown in TSB at 37°C overnight. The fol-
lowing day, 1:10 dilutions of the cultures were made in TSBG and incubated at
37°C for 4 h with shaking. RNA was extracted from 109 cells using the RNeasy
Protect Miniprep kit (QIAGEN) according to the manufacturer’s instructions
except that cells were lysed by vortexing in the presence of 4-mm glass beads for
10 min. Turbo DNase was added to digest contaminating DNA that was then
inactivated by heating according to the manufacturer’s instructions (Ambion).
RNA concentrations were determined by the absorbance at 260 nm, and 1 g of
each sample was analyzed using the Superscript II One-Step reverse transcrip-
tion-PCR (RT-PCR) kit from Invitrogen and primers specific for icaA (5-GTC
TATTTACTGGATTGTCGGTC-3 and 5-GTCTGACTTCGCTTAATACAG
CC-3), icaC (5-CCTTAGTGTTACAATTTTACATTCG and 5-CGTTCGTA
GTTATAACCCATATATGC-3), or gyrase B, as a positive control (5-TTAT
GGTGCTGGGCAAATACAAG-3 and 5-CACCATGTAAACCACCAGATA
C-3). Agarose gels were stained with ethidium bromide and photographed. Each
experiment was performed at least three times.
Biofilm assay. Microtiter plate assays for biofilm production were performed
essentially as described previously by Christensen et al., with minor modifications
(5). Cultures were grown overnight in 2 ml of TSBG, diluted 1:200 in TSBG, and
aliquoted into 96-well polystyrene flat-bottom microtiter plates from Corning
(Corning, NY). After 24 h at 37°C, the wells were emptied and washed twice with
phosphate-buffered saline (PBS). The plates were dried at ambient temperature,
stained for 30 s with safranin, washed under gently running tap water, and
scanned using a digital scanner. The stained biofilms were resuspended in 100 l
PBS by gentle sonication, transferred into new microtiter wells, diluted 1:4 in
PBS, and analyzed by spectrophotometry at an optical density at 450 nm (OD450)
using an enzyme-linked immunosorbent assay reader.
Production of human mAbs. Human monoclonal antibodies (mAbs) were
produced as previously described (19). Briefly, B cells from a patient recovering
from S. aureus infection were transformed with Epstein-Barr virus and screened
for their ability to bind either acetylated PNAG or dPNAG. Immunoglobulin
variable region genes from hybridomas of interest (binding to either PNAG,
dPNAG, or both) were cloned into the immunoglobulin G1 (IgG1)-TCAE6
vector and transfected into CHO cells for the production of fully human IgG1
mAbs. The mAbs secreted by the F598 hybridoma (high binding to both acety-
lated PNAG and dPNAG) and the F628 hybridoma (high binding only to acety-
lated PNAG) resulting from these manipulations (19) were used in the studies
described here.
Immunological detection of PNAG on the cell surface and in culture super-
natants. PNAG blots were performed essentially as described previously (7),
with minor modifications. Bacteria were grown overnight in 5 ml TSBG. The
cultures were diluted in TSB to produce an OD600 of 1.5, and 10 ml was
centrifuged to recover the bacterial cells. The culture supernatant was saved, and
the cell pellet was washed once with 1 ml PBS and then resuspended in 100 l
0.5 M EDTA with gentle sonication, followed by boiling for 5 min. The extracts
were cleared by centrifugation, and extracts and culture supernatants were
treated separately with 200 g proteinase K and incubated at 60°C for 1 h and
then at 85°C for 30 min to inactivate the protease. The cell surface extracts and
culture supernatants were immobilized on nitrocellulose using a vacuum mani-
fold. A 1:1 dilution represents one-half of the surface extract from each culture
and one-quarter of the culture supernatant. Dilutions (1:10 and 1:100) were
made using Tris-buffered saline (TBS). Blots were blocked for 1 h in 1% bovine
serum albumin (BSA) in TBS, probed with 1:1,000-diluted goat antiserum spe-
cific for PNAG (29), which was affinity-purified as described previously (19),
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diluted in TBS–0.05% Tween 20 containing 1% BSA (24) for 2 h at room
temperature, washed, and probed with 1:10,000 swine anti-goat IgG horseradish
peroxidase conjugate in TBS–0.05% Tween 20–1% skim milk for 1 h at room
temperature. Bands were visualized using the ECL kit (Amersham) and auto-
radiography.
Immunofluorescence microscopy. Glass-bottom microwell plates (Mattek,
MA) were coated with 4% Celltak (BD Biosciences, MA) solution for 30 min and
then washed twice with sterile distilled water. Freshly harvested bacterial sus-
pensions were added to the plates, allowed to sit for 20 min at room temperature,
and then washed twice with PBS. S. aureus 10833ica::tetpMUC and S. aureus
10833ica::tetpMUCicaB were fixed in 4% (wt/vol) formaldehyde in PBS for
30 min at 4°C and then washed twice with PBS. Blocking solution containing 1%
BSA and 2% normal rabbit serum (to block nonspecific binding to protein A) in
PBS was added and incubated for 1 h at room temperature with rocking. After
this time, the plates were washed, incubated with a primary antibody solution to
either PNAG (human IgG1 mAb F598) or an isotype control (human IgG1 mAb
F429 specific for Pseudomonas aeruginosa alginate) (34) diluted to 20 g/ml in
blocking buffer, and left for 2 h at room temperature with rocking. After being
washed four times with PBS for 5 min each (with rocking), a secondary antibody
(anti-human IgG) (Alexa 488; Molecular Probes, Corvallis, OR) diluted 1:5,000
in blocking buffer was added. The plate was left rocking at room temperature for
1 h and then washed again with PBS four times for 5 min each with rocking at
room temperature. The plates were examined by phase-contrast and fluores-
cence microscopy. Images of the same field viewed by the two different micro-
scopic methods were acquired by a camera, and images were processed by
computer using the LSM 5 image analysis system.
Opsonophagocytic assays. White blood cells (WBC) were prepared from fresh
human blood collected from healthy adult volunteers. Twenty-five milliliters was
mixed with an equal volume of dextran-heparin buffer and incubated at 37°C for
1 h. The upper layer containing the leukocytes was collected, the cells were
pelleted by centrifugation, and hypotonic lysis of the remaining erythrocytes was
accomplished by resuspension of the cell pellet in 1% NH4Cl and incubation for
10 min at room temperature. WBC were then washed three times and resus-
pended with RPMI with 15% fetal bovine serum (RPMI-FBS). Using trypan blue
staining to differentiate dead from live leukocytes, the final WBC count was
adjusted to 2.5  107 WBC per ml. The complement source (1 ml of baby rabbit
serum diluted 1:10 in RPMI-FBS) was adsorbed at 4°C for 45 min with continual
mixing using bacteria resuspended from a pellet containing 109 CFU of S.
aureus strain MN8. After adsorption, the complement solution was centrifuged
and filter sterilized. The bacterial strains to be evaluated for phagocyte-depen-
dent killing activities of antibody were grown overnight in TSBG, adjusted to an
OD650 of 0.1 with fresh TSBG, and allowed to grow to an OD650 of 0.4. A 1:100
dilution was then made in RPMI-FBS for use in the killing assay. The protocol
for the use of human WBC in these assays was approved by the Brigham and
Women’s Hospital Institutional Review Board.
The opsonophagocytic assay was performed with 100 l of leukocytes, 100 l
of bacteria, 100 l of the complement solution, and 100 l of protein G-purified
mAb F598 or mAb F628 at four different concentrations. Controls were made by
replacing the antibody with RPMI-FBS. The reaction mixture was incubated on
a rotor rack at 37°C for 90 min. The tubes were vortexed for 15 s and diluted in
TSB with 0.25% Tween to prevent bacterial aggregation, and samples were
plated onto tryptic soy agar plates. The percentage of killing was calculated by
determining the ratio of the CFU surviving in the tubes with bacteria, leukocytes,
complement, and antibody to the CFU surviving in the tubes with all these
components but lacking antibody. For antibody-independent phagocytosis, we
calculated the percentage of killing of bacteria by leukocytes and complement
only, comparing the surviving counts with those in tubes lacking either leukocytes
or complement. The assay was performed with triplicate samples and repeated
two to three times.
Inhibition of phagocytosis by competitive assay. PNAG was purified from a
culture of S. aureus MN8m as previously described (16, 27), and a molecule that
was 95% acetylated was obtained. Since mAbs F598 and F628 mediate differ-
ent levels of opsonic killing per microgram of protein, we standardized the assay
by using concentrations of the antibodies that would result in approximately
equivalent levels of opsonic killing. PNAG diluted in RPMI-FBS was used in the
opsonophagocytic reactions described above at three different concentrations,
based on the ratio of IgG used in each assay. Due to the low solubility of PNAG
at neutral pH, a maximum concentration of 200 mg PNAG/liter could be used in
these assays. Control samples consisted of bacteria, leukocytes, complement,
mAb, and PBS without PNAG. The percentage of inhibition of killing was
calculated by determining the ratio of the CFU surviving in the tubes with PNAG
to the CFU surviving in the tubes without PNAG. The assay was done with
triplicate samples and repeated two to three times.
Murine bacteremia model. The animal model used was previously described
(29). Briefly, groups of six mice (FVB-NJ; female, 5 to 7 weeks of age) were
challenged intravenously (i.v.) with a dose of 1.0  107 CFU of S. aureus strains
in 0.2 ml of PBS. Mice were sacrificed 90 min after bacterial challenge, blood
samples were withdrawn, numbers of surviving bacteria were determined by
FIG. 1. Role of IcaB in biofilm formation by S. aureus. S. aureus strain 10833 produces a weak biofilm, which is lost by the deletion of the entire
ica locus (10833ica::tet). Biofilm formation is augmented by the presence of the pMUC plasmid (10833ica::tetpMUC); however, deletion of icaB
from pMUC (10833ica::tetpMUCicaB) results in a phenotype similar to that of the ica mutant. Overexpression of icaB in the parental strain
(10833picaB) enhances biofilm formation. (A) Safranin-stained biofilms of bacteria grown overnight in TSBG in microtiter wells. (B) Quanti-
tative analysis of the stained biofilms after homogenization by sonication in PBS. Bars reflect the mean OD of eight samples, and error bars indicate
the standard deviations. Statistical comparisons (all unpaired t tests) were as follows: for 10833 versus 10833ica::tet, the P value was 	0.001; for
10833 versus 10833picaB, the P value was 0.001; for 10833ica::tet versus 10833ica::tetpMUC, the P value was 	0.001; for 10833ica::tetpMUC
versus 10833ica::tetpMUCicaB, the P value was 	0.001. (C) RT-PCR using RNA from strain 10833 (lane 1), strain 10833ica::tet (lane 2), strain
10833ica::tetpMUC (lane 3), strain 10833ica::tetpMUCicaB (lane 4), and strain 10833picaB (lane 5). Primers specific for icaA transcript
produced a 520-bp PCR product (lanes 1 to 5, left), primers specific for icaC produced a 625-bp product (lanes 1 to 5, center), and primers specific
for the positive control, gyrB, yielded a 250-bp product (lanes 1 to 5, right).
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serial diluting and plating of blood samples, and the results were expressed as
CFU/ml of blood. All animal studies were approved by the Harvard Medical
Area Institutional Animal Care and Use Committee.
Statistical analysis. Quantitative assays were compared using one-way analysis
of variance by applying the Levene’s test of homogeneity of variances, the Tukey
multiple-comparisons test, and also unpaired-sample t tests using SPSS software
(Statistical Package for the Social Sciences). All tests were performed with a
confidence level of 95%.
RESULTS
IcaB is required for biofilm formation in S. aureus. We first
analyzed the biofilm-forming capacity of icaB-overexpressing
and deletion mutant strains of S. aureus. S. aureus strain 10833
produced a moderate biofilm when grown in TSBG, and the
ica deletion mutant, which is unable to produce any PNAG,
elaborated very little biofilm (Fig. 1). When the icaB gene was
overexpressed in strain 10833, however, biofilm formation in-
creased approximately fourfold (P 
 0.001, unpaired t test).
When strain 10833ica::tet was complemented with pMUC,
which contains the ica locus from the PNAG-overproducing
strain MN8m, it produced a heavy biofilm. In-frame deletion of
the icaB gene from pMUC to produce pMUCicaB resulted
in a strain that was phenotypically similar to S. aureus 10833ica::
tet that lacks the ica genetic locus in that S. aureus 10833ica::
tet(pMUCicaB) could not produce a biofilm (P 	 0.001, un-
paired t test between strains carrying pMUC and those carry-
ing pMUCicaB).
Deletion of icaB in pMUC did not induce a frameshift
mutation in the ica locus; nonetheless, we considered the pos-
sibility that the mutation might affect the transcription of the
downstream gene icaC. To assess the transcription of the ica
locus in the absence of icaB, we performed RT-PCR to mea-
sure levels of icaA and icaC transcripts (gyrB transcript levels
were measured as a control). As expected from our previous
findings that ica is constitutively transcribed in pMUC, icaA
and icaC transcript levels in S. aureus 10833ica::tet(pMUC)
were much greater than those in S. aureus 10833, and the levels
of icaA and icaC RNA in S. aureus 10833ica::tet(pMUCicaB)
were comparable to those obtained from S. aureus strain
10833ica::tet(pMUC), indicating that the icaB deletion muta-
tion does not affect the transcription of the icaADC genes in
pMUCicaB (Fig. 1C). Figure 1C also demonstrates, as ex-
pected, that the overexpression of icaB in S. aureus strain
10833(picaB) does not affect the transcription of the icaA and
icaC genes.
IcaB is required for the association of PNAG with the bac-
terial cell surface. Immunoblots were used to characterize the
levels of PNAG in bacterial cell surface extracts and culture
supernatants from the isogenic S. aureus 10833 strains. As
expected, strain 10833ica::tet did not produce any detectable
PNAG (Fig. 2). Some of the PNAG produced by wild-type S.
aureus strain 10833 was found in the supernatant, whereas the
majority of the polysaccharide was cell surface associated (Fig.
2). Placing the pMUC plasmid into strain 10833ica::tet, which
leads to high levels of ica transcripts, augmented PNAG pro-
duction. In S. aureus strain 10833ica::tetpMUC, the majority
of the PNAG was surface associated. In S. aureus strain
10833ica::tetpMUCicaB, however, a minority of the PNAG
was on the surface, and most of it was secreted. In addition, the
IcaB-overexpressing strain (10833picaB) had more PNAG
on the surface than the wild-type parental strain, and none was
detected in the supernatant.
We also evaluated the surface association of PNAG by
immunofluorescent microscopic analyses. S. aureus strains
10833ica::tetpMUC and 10833ica::tetpMUCicaB were
stained with dPNAG-specific mAb F598, and immunofluores-
cence analysis indicated that the mAb bound well to the sur-
face of S. aureus 10833ica::tetpMUC, but staining of S. aureus
10833ica::tetpMUCicaB was not seen (Fig. 3). At no mag-
nification under which these cells were examined could any
fluorescence be detected. No fluorescence more than 10%
above the background was observed with either S. aureus strain
when a human IgG1 isotype control antibody was used in place
of mAb F598 (not shown). Together, these results indicate
that, similar to S. epidermidis, IcaB is required for the optimal
association of PNAG with the bacterial cell surface in S. aureus
as well as the formation of a strong biofilm in tissue culture
wells.
Opsonophagocytic assays. We compared phagocyte and
complement-dependent killing by human mAb F598, which
reacts with both dPNAG and native PNAG antigens, and mAb
F628, which reacts optimally with the highly acetylated native
PNAG molecule but has little antigen binding activity when
acetates are removed (19). In addition, mAb F598 has notably
better antigen binding activity to native PNAG than mAb
F628, which is indicative of a potentially greater affinity in
binding to this antigen (19). Killing of S. aureus 10883 and S.
aureus 10833(picaB) mediated by mAbs F598 and F628
showed that mAb F598 had higher killing activity than mAb
F628 for both strains (P 	 0.001, unpaired t test) (Fig. 4A).
Overexpression of IcaB in S. aureus 10833(picaB) enhanced
the killing by dPNAG-binding mAb F598 compared to the
opsonic killing of wild-type S. aureus 10833 (P 	 0.001, un-
paired t test) (Fig. 4A). There was no opsonic killing in the
FIG. 2. IcaB is required for the association of PNAG with the
bacterial cell surface. S. aureus 10833 produces PNAG, the majority of
which is surface associated. Strain 10833ica::tet does not produce de-
tectable PNAG. Complementation of the ica deletion with plasmid
pMUC (10833ica::tetpMUC) resulted in enhanced PNAG produc-
tion, with the majority present in surface extracts. Deletion of icaB
from plasmid pMUC (10833ica::tetpMUCicaB) did not prevent
PNAG synthesis but resulted in the secretion of most of the polysac-
charide into the culture supernatant. Overexpression of icaB in the
parental strain (10833picaB) resulted in an increase in PNAG pro-
duction, with essentially all of the polysaccharide retained on the cell
surface.
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absence of mAb, polymorphonuclear leukocyte (PMN), or
complement in the reaction tubes, as these values served to
calculate the percentage of bacteria killed.
Figure 4B presents the results of the opsonic killing assays
using S. aureus strains 10833ica::tetpMUC and 10833ica::tet
pMUCicaB. The PNAG-overproducing S. aureus strain 10833ica::
tetpMUC was effectively killed by dPNAG-binding mAb F598
but relatively resistant to the opsonic killing effect of native
PNAG-binding mAb F628 (P 	 0.001, unpaired t test). Of
note, in the absence of mAb,60% of S. aureus strain 10833ica::
tet and 50% of S. aureus strain 10833ica::tetpMUCicaB were
killed by phagocytes and absorbed complement alone, indicat-
ing that a loss of the cell surface PNAG resulted in a marked
increase in the susceptibility to antibody-independent killing
compared to killing in the absence of either phagocytes or
complement (Fig. 5). There was no killing of any strain in the
absence of PMN or complement (data not shown). When we
tested mAbs F598 and F628 for opsonic killing of S. aureus
strain 10833ica::tetpMUCicaB (Fig. 4B), there was no en-
hancement of bacterial killing over that achieved in the pres-
ence of only phagocytes and complement (P  0.05, unpaired
t test), consistent with the low level of PNAG on the surface of
this strain.
Inhibition of phagocytosis by competitive assay. To test the
hypothesis that non-cell-associated PNAG can act as a decoy
FIG. 3. Evaluation of surface-associated PNAG by S. aureus
strains by immunofluorescence. (A and B) Fluorescence (A) and
phase-contrast (B) microscopy of immunostained S. aureus strain
10833ica::tetpMUCicaB. (C and D) Fluorescence (C) and phase-con-
trast (D) microscopy of immunostained S. aureus 10833ica::tetpMUC.
PNAG was visualized by reactions with human mAb F598 and secondary
anti-human IgG conjugated to Alexa 488.
FIG. 4. Opsonophagocytic activity of human IgG1 mAbs F598 (dPNAG and native PNAG binding) and F628 (native PNAG binding only)
against S. aureus strains. The legend indicates which mAb was used against the four different S. aureus strains. Symbols represent means, and error
bars represent standard deviations.
FIG. 5. Antibody-independent phagocytosis of S. aureus strains.
Survival of an initial inoculum of 5  105 CFU of each strain after
incubation at 37°C for 90 min with 2 105 PMN and 20% infant rabbit
serum as a complement source is shown. Bars represent means, and
error bars represent standard deviations. S. aureus strain 10833 has a
significantly higher survival rate than strain 10833ica::tet (P 	 0.001,
unpaired t test), whereas 10833ica::tetpMUC has a higher survival
rate than strain 10833ica::tetpMUCicaB (P 	 0.001, unpaired t
test).
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to the PNAG-specific opsonic antibody, we added purified,
highly acetylated (95%) PNAG to opsonophagocytic reac-
tions mediated by either mAb F598 or mAb F628 against S.
aureus strain 10833. Table 1 presents the percentage of inhi-
bition of killing achieved compared to that of control tubes
without added PNAG. When we used a 1:1 (wt/wt) ratio of
PNAG antigen to mAb, phagocytosis mediated by dPNAG-
binding mAb F598 was inhibited only 6%. When we used
native PNAG-binding mAb F628 under the same conditions,
the inhibition level, 36%, was significantly higher (P 
 0.001,
unpaired t test). The greater ability of highly acetylated PNAG
to inhibit killing mediated by the mAb to native PNAG com-
pared to the mAb that can also bind to dPNAG was further
verified with the other PNAG-to-IgG ratios that we tested
(Table 1). We could not test inhibition by higher ratios of
PNAG to mAb F628 due to the poor solubility of the antigen
at neutral pH at higher concentrations.
Murine bacteremia model. The role of icaB in S. aureus
survival in the blood of mice following i.v. injection was eval-
uated using two different comparisons of paired strains. The
first involved comparing the survival of the IcaB-overexpress-
ing strain with that of the wild-type parental strain, and the
second involved comparing the ica deletion strain carrying
pMUC to restore PNAG production with the same strain car-
rying pMUCicaB. When IcaB was overexpressed in S. aureus
10833, significantly more bacteria survived in the blood after 90
min (P 	 0.001, unpaired t test) than in the wild-type parental
strain (Fig. 6A). On the other hand, when the icaB gene was
deleted from the pMUC locus (Fig. 6B), a significantly lower
number of bacteria survived than that of bacteria carrying the
intact pMUC plasmid (P 	 0.001, unpaired t test). Thus, the
overexpression of IcaB enhanced the surface retention of
PNAG and enhanced resistance to mouse mediators of bacte-
rial clearance from the blood, whereas the deletion of icaB
increased the clearance of S. aureus from mouse blood.
DISCUSSION
One known strategy that pathogens use to avoid host im-
mune defenses is to elicit high levels of poorly protective an-
tibodies. The protective efficacy of antibodies may be poor due
to low antibody affinity (35), the production of an inappropri-
ate antibody isotype (2, 32), or specificity for nonprotective
epitopes (39). This last strategy appears applicable to the im-
mune response to staphylococcal PNAG, wherein antibodies
that bind best to the immunodominant epitopes on highly
acetylated antigen function poorly in opsonic killing and pro-
tection assays (29). Overcoming this evasive strategy by immu-
nizing animals with a conjugate vaccine containing poorly
acetylated dPNAG elicited antibodies that were superior to
those to native PNAG in opsonic killing and protection against
systemic S. aureus infection (29). However, the molecular basis
for the superior efficacy of the dPNAG-specific antibodies was
not apparent in the data reported in that prior publication.
The results reported here indicate that in the absence of the
IcaB protein, less PNAG is preferentially retained on the S.
aureus cell surface, as it is for S. epidermidis (40), presumably
due to a lack of N-deacetylase activity in the absence of IcaB.
We speculate that in the presence of IcaB deacetylase activity,
the PNAG retained on the S. aureus cell surface is less able to
react with antibody to native PNAG and better able to bind
antibody to dPNAG, potentially improving opsonic killing and
protection. Increasing the N-deacetylase activity by the over-
expression of icaB increased S. aureus susceptibility to killing
by a human IgG1 mAb able to bind well to dPNAG but had no
effect on killing by a human IgG1 mAb that binds only to native
PNAG. Also, increased expression of icaB leads to greater
survival of this strain in mouse blood, indicating a crucial role
for surface-associated PNAG in bacterial resistance to anti-
body-independent opsonic killing. In contrast, a loss of icaB
resulted in a strain with decreased surface retention of PNAG,
increased susceptibility of the strain to antibody-independent
killing, and reduced survival in the blood of infected mice.
These findings point to a key role for the IcaB protein in
pathogenesis due to its ability to influence the amount of
PNAG on the S. aureus cell surface.
Vuong et al. (40) initially determined that the icaB gene is
responsible for the deacetylation of PNAG (referred to as
PIA) in S. epidermidis and that the deacetylation is necessary
for the surface retention of PNAG. The results from our study
confirmed that IcaB is needed for the surface retention of
PNAG in S. aureus strains. Given the high homology of the
icaB genes in S. epidermidis and S. aureus and the identical
effects that they mediate in regard to PNAG surface retention
in both organisms, it is almost certain that IcaB in S. aureus
also functions as an N-deacetylase. Surface retention of PNAG
promotes the adherence of staphylococci to various plastics
and glass and is necessary for biofilm formation in many, but
FIG. 6. Murine bacteremia model demonstrates the role for
IcaB in enhanced survival of S. aureus in vivo. The bars represent
the mean numbers of bacteria that were recovered from blood 90
min after i.v. infection, and the error bars indicate standard devia-
tions. Wild-type S. aureus 10833 survives less well than S. aureus
10833picaB (IcaB overexpresser) (P 	 0.001, unpaired t test);
S. aureus 10833ica::tetpMUC survives better than S. aureus
10833ica::tetpMUCicaB (P 	 0.001, unpaired t test).
TABLE 1. Inhibition of opsonophagocytic activity of human IgG1
mAbs F598 and F628 against S. aureus wild-type strain 10833
by highly acetylated PNAG
mAb
used
Concn
(mg/liter)
PNAG:IgG
ratio
%
Inhibition
F598 6 1:1 6  7
4:1 25  12
10:1 36  5
F628 50 1:1 32  12
4:1 57  13
VOL. 75, 2007 PROTECTIVE BASIS FOR ANTIBODY TO PNAG 3411
 by on June 20, 2007 
iai.asm
.org
D
ow
nloaded from
 
not all (1), strains. Therefore, without icaB, PNAG can no
longer function in the role of a polysaccharide adhesin, and
biofilms cannot form in the absence of surface-retained
PNAG. As it is well established that biofilm formation renders
bacterial cells more resistant to the immune system (24) and to
antibiotic therapy (14) and biofilm formation is an important
virulence factor in S. epidermidis device-related infections (36,
37), the IcaB protein of staphylococci clearly plays a key role in
the pathogenesis of biofilm infections by modulating the at-
tachment of PNAG to the staphylococcal cell surface.
The results reported here, along with those reported previ-
ously by Vuong et al. (40), indicate that the PNAG polymer
must be anchored to the bacterial cell to form biofilms; PNAG
cannot function merely as a sort of intercellular glue binding
cells together. Although PNAG was first found to be associ-
ated with the production of biofilms in staphylococcal strains,
it has now been shown to play a role in biofilm formation by a
variety of bacterial species including Escherichia coli, Yersinia
pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, Actino-
bacillus pleuropneumoniae, and Bordetella pertussis among oth-
ers (17, 33, 41). Whether IcaB homologs within the genomes of
these other organisms have a similar function in regard to
biofilm formation is not known. However, Wang and col-
leagues showed that a deletion of the icaB-homologous gene in
E. coli, designated pgaB, resulted in a loss of biofilm formation
for this organism (41).
Our findings also suggest that the secreted form of PNAG
may act as a decoy by binding potentially opsonic antibodies
away from the cell surface, preventing them from mediating
killing. Importantly, the inhibition of binding of a human IgG1
mAb that reacts only with native PNAG compared to the
inhibition achieved with a human IgG1 mAb that can also bind
to dPNAG suggests that non-cell-associated PNAG may con-
tribute to bacterial resistance to antibody-dependent opsonic
killing when antibodies to native PNAG are present.
When the findings reported here are integrated with the
findings of other studies that indicate that highly acetylated
PNAG may also play a role in virulence by eliciting a less
protective antibody response to this antigen (29), it appears
that there are multiple properties of this molecule that con-
tribute to the pathogenesis of staphylococcal infections. Effec-
tively overcoming the immunodominance of the poorly protec-
tive epitopes associated with a high level of acetylation by use
of dPNAG conjugate vaccines was a critical step in furthering
the development of PNAG as a vaccine target (29). Confirming
the superior opsonic activity of a human mAb capable of bind-
ing to dPNAG over that of a human mAb that binds best to
native PNAG (19) provided further support for our conclusion
that antibody to the surface-retained form of PNAG provides
better protection against staphylococcal infection. Studies of
antibodies with specificity for either native PNAG or dPNAG
isolated by affinity chromatography from the sera of S. aureus-
infected cystic fibrosis patients (20) also showed superior op-
sonic killing mediated by the antibodies with specificity to
dPNAG. The results from the studies reported here showing
the effects of the loss of expression of IcaB and overexpression
of IcaB on the ability of S. aureus to form biofilms, resist
antibody-independent opsonic killing, and survive in mouse
blood not only explain, in part, the role of PNAG in these
varied aspects of S. aureus virulence but also point to a reason
why antibody to dPNAG has greater opsonic and protective
efficacy. With preferential retention of the deacetylated form
of the antigen on the cell surface, there is now a molecular
basis for understanding why the antibodies to dPNAG function
in a superior fashion compared to those that bind less well to
the antigen when acetate groups are reduced. This insight
should help guide further vaccine development based on the
PNAG molecule, supporting the pursuit of the dPNAG form
of the antigen as a vaccine candidate.
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